Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (PREDIXIIHER2)

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint inhibitor atezolizumab or not.

Study Overview

• Status: Terminated
• Conditions: HER2-positive Breast Cancer; Early-stage Breast Cancer
• Intervention / Treatment: Drug: Docetaxel; Drug: Carboplatin; Drug: Trastuzumab; Drug: Pertuzumab; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Atezolizumab; Drug: Trastuzumab emtansine; Drug: Paclitaxel

Detailed Description

The primary aim is to investigate whether the rate of pCR, after optimal neoadjuvant anti-HER2 based systemic therapy, can be increased by addition of atezolizumab.

Secondary aims are to assess safety and tolerability of this treatment combination, and to identify therapy predictive factors for the anti-HER2 monoclonal antibodies trastuzumab and pertuzumab plus-minus atezolizumab with a backbone of chemotherapy, using modern molecular biological investigational procedures with analyses by repeated biopsies from an intra-patient longitudinal study design.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 2

Contacts and Locations

Study Locations

• Sweden
  • Göteborg, Sweden
    • Sahlgrenska Universitetssjukhuset
  • Malmö, Sweden
    • Skanes universitetssjukhus
  • Stockholm, Sweden
    • Södersjukhuset
  • Stockholm, Sweden
    • S:t Görans sjukhus
  • Stockholm, Sweden, SE-17176
    • Karolinska Universitetssjukhuset
  • Sundsvall, Sweden
    • Länssjukhuset Sundsvall
  • Umeå, Sweden
    • Norrlands universitetssjukhus
  • Örebro, Sweden
    • Örebro Universitetssjukhus

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Confirmed PD-L1 expression ≥1% on tumour cells and/or TILs (prescreening phase)
• Able to provide written informed consent
• Female gender
• Patients with breast cancer confirmed by histology, characterised by immunohistochemistry for ER, PR, HER2 and proliferation marker.
• HER2 amplification, IHC 3+ and preferably confirmed by ISH
• Tumor and blood samples available.
• Age 18 years or older. Elderly patients in adequate condition for the planned therapy, which may be supported by a geriatric assessment (according to ASCO guideline; Mohile et al, JCO 2018)
• Primary breast cancer >20 mm in diameter or verified lymph node metastases
• Adequate bone marrow, renal and hepatic functions (see Table 1)
• LVEF ≥50%
• ECOG performance status 0-1

Exclusion Criteria:

• Distant metastases without chance to cure, including node metastases in the contralateral thoracic region or in the mediastinum. An exception is presence of at most 2 morphologically characterized well-defined distant metastases accessible for stereotactic radiotherapy, provided that this treatment is available at the participating centre.
• Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix
• Patients in child-bearing age without adequate contraception
• Pregnancy or lactation
• Uncontrolled hypertension, heart-, liver-, or kidney-diseases or other medical/psychiatric disorders.

• History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis

  • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study. Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.

  • Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., no psoriatic arthritis) are permitted provided that they meet the following conditions:

    • Rash must cover less than 10% of body surface area (BSA)
    • Disease is well controlled at baseline and only requiring low potency topical steroids
    • No acute exacerbations of underlying condition within the last 12 months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids).
• Vaccination with a live vaccine within 30 days of the first dose of study treatment
• A known history of Human Immunodeficiency Virus (HIV) infection, hepatitis B (HBsAg reactive) or hepatitis C (HCV RNA detected) infection or active tuberculosis.

• Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial

  • Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study
  • Patients with a history of allergic reaction to IV contrast requiring steroid pre- treatment should have baseline and subsequent tumor assessments performed using MRI.
  • The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.
• Hypersensitivity to atezolizumab

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A: Experimental; Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide + atezolizumab. In total seven courses of preoperative treatment. Response evaluations after course four. Postoperatively, if pathologic complete response, patients receive 14 courses of adjuvant trastuzumab every third week. If no pCR patients receive 14 courses of T-DM1 every third week.	Drug: Docetaxel; 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.; Drug: Carboplatin; AUC 6 iv, day 1 every third week, 4 courses preoperatively.; Drug: Trastuzumab; 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.; Other Names: Herceptin; Drug: Pertuzumab; 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.; Other Names: Perjeta; Drug: Epirubicin; 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively; Drug: Cyclophosphamide; 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively; Drug: Atezolizumab; 840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.; Other Names: Tecentriq; Drug: Trastuzumab emtansine; 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.; Other Names: Kadcyla; Drug: Paclitaxel; 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
Active Comparator: B: Standard; Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide. In total seven courses of preoperative treatment. Response evaluations after course four. Postoperatively, if pathologic complete response patients receive 14 courses of adjuvant trastuzumab (combined with pertuzumab in case of high-risk disease features) every third week. If no pCR patients receive 14 courses of T-DM1 every third week.	Drug: Docetaxel; 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.; Drug: Carboplatin; AUC 6 iv, day 1 every third week, 4 courses preoperatively.; Drug: Trastuzumab; 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.; Other Names: Herceptin; Drug: Pertuzumab; 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.; Other Names: Perjeta; Drug: Epirubicin; 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively; Drug: Cyclophosphamide; 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively; Drug: Trastuzumab emtansine; 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.; Other Names: Kadcyla; Drug: Paclitaxel; 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of pathological objective response to primary medical treatment	Efficacy measure at surgery that is performed 2-3 weeks after 7 cycles (each cycle lasts 21 days) of preoperative treatment.	At surgery 2-3 weeks after the last (of 7) cycles of neo-adjuvant systemic therapy.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate	Proportion of patients with reduction in tumour burden ≥30% according to RECIST	After the 4th and 7th cycle (each cycle is 21 days)
Distant disease-free survival	Time from randomisation to distant metastases or death due to breast cancer	During the study period up to 10 years
Event-free survival	Time from randomisation to breast cancer relapse, contralateral breast cancer, other malignant neoplasms, or death from any cause	During the study period up to 10 years
Overall survival	Time from randomisation to death from any cause	During the study period up to 10 years
Rate of breast conserving surgery	Rate	At surgery
Incidence of treatment-emergent adverse events (Safety)	Rate of grade 3-4 toxicity, rate of % of discontinuation of study medication due to toxicity, rate of AE's of special interest	During the 18-week period of treatment and until 30 days after termination and during the follow-up period up to ten years
Differences in PROMs according to EORTC C30	Health related Quality of Life using the EORTC C30 scale (EORTC Quality of Life questionnaire C30)	At baseline, after cycle 4 (a cycle is 21 days), after cycle 7 (a cycle is 21 days), 2 months, 1 year and 5 years after surgery
Differences in PROMs according to EORTC BR23	Health related Quality of Life using the EORTC BR23 scale (EORTC Quality of Life breast specific questionnaire BR23)	At baseline, after cycle 4 (a cycle is 21 days), after cycle 7 (a cycle is 21 days), 2 months, 1 year and 5 years after surgery
Differences in objective cognitive function	Assessed by an online neuropsychological test (Amsterdam Cognition Scan, validated for use in breast cancer patients [Feenstra et al, J Clin Exp Neuropsychol. 2018 Apr;40(3):253-273. ])	At baseline, 3 months after surgery, one and five year after treatment start
Treatment prediction, PD-L1	% of Programmed Death Ligand 1 expressing cells [tumour cells and tumour infiltrating lymphocytes]	At baseline, after the 4th cycle (each cycle is 21 days), at surgery and annually during the post-surgical follow-up period up to five years
Treatment prediction, TMB	Tumour-mutational burden (total number of nonsynonymous mutations per coding area of a tumor genome)	At baseline, after the 4th cycle (each cycle is 21 days), at surgery and annually during the post-surgical follow-up period up to five years
Treatment prediction, TILs	Percentage of tumour infiltrating lymphocytes	At baseline, after the 4th cycle (each cycle is 21 days), at surgery and annually during the post-surgical follow-up period up to five years
Treatment prediction, composition of faeces microbiome	Composition of bacterial strains in gastro-intestinal flora (% of different strains measured with DNA/RNA analysis and in microbiotic culture)	At baseline, after 7th cycle (each cycle is 21 days) before surgery, and one year after surgery
Differences in PROMs	Symptoms using the Memorial Symptoms Assessment Scale (MSAS). The 32-item MSAS scale includes occurrence, frequency, severity, and distress associated with each symptom using four- and five-point rating scales. Symptom burden is calculated as the average of frequency, severity and distress of each symptom. Higher scores indicates higher symptom burden.	At baseline, after cycle 4 (each cycle is 21 days), after cycle 7 (each cycle is 21 days), 2 months, 1 year and 5 years after surgery

Collaborators and Investigators

• Sponsor: Renske Altena
• Investigators: Principal Investigator: Renske Altena, MD, PhD, Karolinska University Hospital; Study Director: Jonas Bergh, MD, PhD, Karolinska Institutet

Study record dates

Study Major Dates

• Study Start (Actual): May 23, 2019
• Primary Completion (Actual): June 30, 2021
• Study Completion (Actual): June 30, 2021

Study Registration Dates

• First Submitted: March 21, 2019
• First Submitted That Met QC Criteria: March 26, 2019
• First Posted (Actual): March 28, 2019

Study Record Updates

• Last Update Posted (Actual): September 23, 2021
• Last Update Submitted That Met QC Criteria: September 22, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: Neoadjuvant therapy; PD-L1 positive breast cancer
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Antibiotics, Antineoplastic; Docetaxel; Cyclophosphamide; Carboplatin; Trastuzumab; Epirubicin; Maytansine; Atezolizumab; Ado-Trastuzumab Emtansine; Pertuzumab
• Other Study ID Numbers: PREDIX II HER2; 2018-004457-24 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes